Compliance 57(4) as on 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has submitted its quarterly compliance under SEBI's Regulation 57 for the period ended September 30, 2025. The company informed BSE that this regulation does not apply to it because it does not have any non-convertible securities with interest, dividend, or principal payments due during the quarter. The letter was signed by Dr. K. Koteswara Rao, Chairman and Managing Director. This is a routine regulatory filing rather than a substantive corporate action.
No material impact on shareholders or stock price — this is a routine non-applicability disclosure confirming the company has no outstanding non-convertible debt obligations requiring disclosure.